Home > Formulary : Adult > Recent Decisions > 2017 >
Decisions 5th September 2017
At the meeting on the 5th September the following decisions were agreed:
New Drug Requests
Approved
Betamethasone soluble tablets (TLS orange/green)
- Approved for inclusion onto the formulary for topical management of oral ulceration/oral erosions and inflammation. TLS depending on indication and whether more general or specialist indication. TLS green for recurrent aphthous ulceration and non-specific oral ulceration and inflammation. TLS Amber one month for oral lichen planus, behcet’s syndrome, pemphigus vulgaris, pemphigus vulgaris, pemphigoid, lupus, oral erythema multiforme, oral-facial granulomatosis
Isavuconazole (TLS Red)
- Approved for inclusion onto the formulary for treatment of invasive aspergillosis and mucormycosis in haematology/bone marrow transplant (BMT) patients as per trust guidelines.
Sucroferric oxyhydroxide (TLS Red)
- Approved for inclusion onto the formulary for management of hyperphosphataemia in dialysis patients with serum phosphate levels that are not controlled after calcium based binder, sevelamer and/or lanthanum have been tried or in patients intolerant to other agents
Shared Care Protocols/TLS Change in Status
Ticagrelor
- SCP updated
Denosumab
- SCP updated to reflect MHRA alert on osteonecrosis of the jaw
Melatonin
- For paediatric use
- Children with neurodevelopmental disorder/disability with intrinsic sleep disorder (difficulty getting to sleep or remaining asleep) who have exhausted all behavioural sleep hygiene options)
- Not for use in ADHD or Autism or Learning Disabilities
Degarelix (TLS Red to Amber)
- SCP needs to reviewed and discussed in a future JFG.